Doses studied
Ipamorelin dosage, as the studies actually ran it
The doses, routes, and pharmacokinetics on record — reported third-person from the literature, never as a protocol to follow.
The short version
This page describes the ipamorelin dosage figures that appear in published studies — what researchers gave, to which species, by which route. It is not a how-to. Most human numbers come from two studies: a pharmacology study using IV infusions of 4.21–140.45 nmol/kg [2], and a Phase 2 trial using 0.03 mg/kg IV twice daily for up to a week [3]. Animal studies used micrograms-per-day under the skin for bone work [4] and milligrams-per-kilogram for the 2024 ferret study [5]. The human half-life is about two hours [2]. Community 'stack' regimens with CJC-1295 have no peer-reviewed human dosing basis and are described here only as anecdotal, never recommended.
Doses and routes on record
Across the literature, ipamorelin has been administered as follows. In the human pharmacokinetic study, single IV infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg ran over 15 minutes each [2]. In the Phase 2 ileus trial, the dose was 0.03 mg/kg IV twice daily on postoperative days 1–7 or until discharge [3]. In the rat bone-growth study, subcutaneous ipamorelin was 18, 90, or 450 µg/day, divided three times daily for 15 days [4]. In the 2024 ferret cachexia study, the dose was 1–3 mg/kg intraperitoneal [5]. Routes studied include intravenous (human PK and clinical trials; rodent efficacy), subcutaneous (rodent bone and body-composition work, and the dominant route in community use), intranasal (rodent PK, ~20% bioavailability), and intraperitoneal (rodent and ferret models). Ipamorelin itself is not orally bioavailable; only engineered analogs achieved meaningful oral absorption (~10% in dogs) [9].
Half-life and pharmacokinetics
Ipamorelin's terminal half-life is about 2 hours in healthy human volunteers given IV infusions, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse peaking roughly 40 minutes (0.67 h) after dosing [2]. The kinetics were dose-proportional across the tested range — doubling the dose roughly doubled exposure, with no saturation [2]. In rats, plasma clearance is roughly five-fold lower than GHRP-6. These are the measured pharmacokinetics, not a schedule; they describe how the molecule behaves, not how anyone should use it.
How much cjc-1295 ipamorelin should i take
How much cjc-1295 ipamorelin should i take is a question with no evidence-based answer, and this site does not provide a dose. There is no peer-reviewed human dosing protocol for ipamorelin alone or for the CJC-1295 combination; the only human ipamorelin doses on record are the IV research figures above [2][3], not subcutaneous self-administration regimens. The popular stack is supported by separate single-agent pharmacology, not by any human trial of the combination for any outcome [14]. Community subcutaneous protocols circulate widely, but they have no controlled-trial basis and are described here only as anecdotal, never as a recommendation.
How to reconstitute cjc-1295 ipamorelin 5mg
How to reconstitute cjc-1295 ipamorelin 5mg is a peptide-handling question rather than a dosing one, and the literature speaks only in general terms. Ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction, and the human pharmacokinetics on record were measured for IV administration, not reconstituted subcutaneous mixtures [2].